Inovio Pharma (INO) Misses Q4 EPS by 6c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.16 --0%
EPS Growth %: +60.7%
Financial Fact:
Total operating expenses: 32.74M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +60.7%
Financial Fact:
Total operating expenses: 32.74M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.34), $0.06 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.39 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- LG Energy 2q Oper Profit 113.3b Won, Est. 210.66b Won - Bloomberg
- Samsung 2q Oper Profit 89.40t Won, Est. 84.2t Won
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
